Oral Lichen Planus and Features in the Short Chain Fatty Acid Pattern Produced by Colonic Fermentation

Umida A. Shukurova*, PhD; Olga E. Bekjanova, PhD, ScD
Tashkent State Dental Institute
Tashkent, Uzbekistan

Abstract

The aim of the study was to assess the content of short chain fatty acids (SCFAs) in feces of patients with different clinical forms of oral lichen planus (OLP).

Materials and Methods: The study included 139 patients with different clinical forms of OLP in the acute stage. The diagnosis of OLP was performed according to both clinical and histopathological criteria. Patients were distributed in four groups according to the clinical form of OLP. Group 1 included 36 patients with the reticular form of OLP; Group 2 included 34 patients with the exudative-hyperemic form of OLP; Group 3 included 27 patients with the erosive-ulcerative form of OLP; Group 4 included 42 patients with the bullous form of OLP. The four groups to be compared were randomized by sex and age. The control group consisted of 40 healthy, age-matched, randomly selected persons without clinical and instrumental signs of OLP and other diseases of the oral cavity. The concentration of SCFAs in feces was evaluated by gas-liquid chromatography. The profiles (specific concentration) of C2, C3, and C4 acids, the ratio of iso-acids to straight-chain acids (iso-Cn/Cn) and iso-C5/C5 were also calculated.

Results: Three types of SCFA changes reflecting the activity of certain groups of microorganisms were found. For all types of the SCFA disorders, we found a marked increase in the iso-C5/C5 ratio. The severity of dysbiosis increased with the severity of clinical forms of OLP. Changes in the qualitative and quantitative contents of SCFAs reflect the disturbances in gut microbiocenosis in LPO patients, which may be one cause for aggravation of the pathological process. (Int J Biomed. 2016;6(1):74-77).

Keywords: oral lichen planus; short chain fatty acids; microbiota; dysbiosis.

Introduction

Lichen planus (LP) is a chronic systemic inflammatory disease that affects the skin and mucous membranes. LP occurs in 0.1 to 4% of the general population, most often in perimenopausal women. Oral LP (OLP) is a mucosal subtype of LP that most commonly occurs in middle-aged adults; the population frequency of OLP is 0.5% to 2.2%. The etiology of this disorder remains uncertain. Several immunological mechanisms of its pathogenesis have been proposed, including antigen-specific cell-mediated immune response, nonspecific immunological mechanisms, autoimmune response, and humoral immunity [1]. OLP is the target of much controversy, mainly in relation to its pathogenesis and possible potential for malignancy. OLP is usually regarded as a multifactorial disease in which endogenous and exogenous factors, in addition to genetic defects, can play a role in the formation and nature of the pathological process.

As is known, disorders of oral mucosa and the gastrointestinal tract may occur simultaneously as a manifestation of a generalized disorder. Human mucosal sites are colonized by an astonishing number of microorganisms of different genera (e.g., Bifidobacterium, Eubacterium, Fusobacterium, Escherichia and Candida). Most of these non-human cells are located in the gastrointestinal tract (GIT) where they exert protective (i.e., natural defense barrier and production of anti-microbial factors), structural (i.e., development of immune system and induction of IgA), and metabolic (i.e., fermentation of non-digestible dietary residues, synthesis of vitamins and ion absorption) functions [2].

Important effects of these microorganisms and their products have been demonstrated not only in the GI tract but also in adipose tissue, immune and nervous systems [3-5]. Short chain fatty acids (SCFAs), which are the major metabolic products of anaerobic bacteria fermentation, have been suggested to be the link between microbiota and host
tissues. SCFAs, also called volatile fatty acids because of their relatively more volatile nature compared to longer fatty acids, have been studied for more than a century. The concentration of these fatty acids in the GIT may predispose to or prevent a large number of pathological conditions. Modifications in the concentrations or the ability of host tissues to use SCFAs have been described in these conditions [6-11].

Acetate, propionate, and butyrate are found in the human intestine at concentrations of approximately 13 mM in the terminal ileum, ~130 mM in the caecum, and ~80 mM in the descending colon [12]. They are produced by anaerobic fermentation of non-digestible dietary residues and endogenous epithelial-derived mucus in the gut. SCFAs released in the intestinal lumen are readily absorbed and used as an energy source by colonocytes (5 to 10% of human basal energy requirements are provided by SCFAs) and also by other tissues, including liver and muscle [13]. SCFAs, of which butyrate is the most studied, modulate different processes, including cell proliferation and differentiation, hormone secretion (e.g., leptin and peptide YY) [14,15], and activation of immune/inflammatory responses [5,16]. Therefore, in addition to energy supply, these fatty acids have other important functions [18].

The aim of the study was to assess the content of SCFAs in feces of patients with different clinical forms of OLP.

Materials and Methods

The study included 139 patients (mean age with different clinical forms of OLP in the acute stage. Inspection of the oral cavity was carried out by the usual method (Borovsky EV et al., 2001). The diagnosis of OLP was performed according to both clinical and histopathological criteria [19]. Patients were distributed in four groups according to the clinical form of OLP. Group 1 included 36 patients with the reticular form of OLP; Group 2 included 34 patients with the exudative-hyperemic form of OLP; Group 3 included 27 patients with the erosive-ulcerative form of OLP; Group 4 included 42 patients with the hyperemic form of OLP; Group 3 included 27 patients with the erosive-ulcerative form of OLP; Group 4 included 42 patients with the hyperemic form of OLP; Group 4 included 42 patients with the erosive-ulcerative form of OLP.

For all types of the SCFA disorders, we found a marked increase in the iso-C5/C5 ratio, indicating an increase in the activity of pathogenic and/or opportunistic pathogens.

Three types of SCFA changes reflecting the activity of certain groups of microorganisms were found (Table 1). Type 1 was characterized by slight changes in the total content, composition, and spectrum of SCFAs, indicating moderate changes in the activity of obligate and facultative anaerobic microflora. Type 2 was characterized by a change in the total number and profiles of C2-C4, indicating the predominant activity of the anaerobic microorganisms, mainly genera Bacteroides, Clostridium, Eubacterium, Fusobacterium, Coprococcus and the strains of the anaerobic microorganisms with proteolytic activity. Type 3 was characterized by changes in the SCFA spectrum, which were associated with the increased activity of the aerobic microorganisms having hemolytic activity (E. Coli, enterococci, streptococci, staphylococci, hemolytic strains of E. Coli, Klebsiella, Proteus, etc.).

For all types of the SCFA disorders, we found a marked increase in the iso-C5/C5 ratio, indicating an increase in the proteolytic activity of facultative, aerobic, and anaerobic microorganisms. The pronounced negative values of the AI ratio, compared with reference values, reflect the changes in the intestinal microflora which contributed to the growth of anaerobic microorganisms.

It should be noted that the severity of dysbiosis increases with the severity of clinical forms of OLP. For example, Type 1 was identified in patients of Groups 1 and 2 with a marked increase in the iso-C5/C5 ratio by 20.67% and 40.66%, respectively. Type 2 was identified in patients of all groups, with a more marked increase in the iso-C5/C5 ratio (from 74.7% for Group 1 to 250% for Group 4). Type 3 was also identified in patients of all groups with an increase in the iso-C5/C5 ratio by 128% to 183.3% (Table 1).
Table 1.
Fecal short-chain fatty acids in patients with different clinical forms of OLP

<table>
<thead>
<tr>
<th>Group</th>
<th>Type</th>
<th>n (mg/l)</th>
<th>C2 (U)</th>
<th>C3 (U)</th>
<th>C4 (U)</th>
<th>AI</th>
<th>iso-Cn/Cn</th>
<th>Iso-C5/C5</th>
</tr>
</thead>
<tbody>
<tr>
<td>The control</td>
<td></td>
<td></td>
<td>0.63±0.02</td>
<td>0.188±0.008</td>
<td>0.174±0.005</td>
<td>-0.567±0.02</td>
<td>0.428±0.02</td>
<td>1.50±0.07</td>
</tr>
<tr>
<td>Group 1</td>
<td></td>
<td></td>
<td>12.32±0.55*</td>
<td>0.60±0.02^*</td>
<td>0.202±0.008^*</td>
<td>0.196±0.004^*</td>
<td>-0.661±0.03^*</td>
<td>0.471±0.02^*</td>
</tr>
<tr>
<td></td>
<td>I</td>
<td></td>
<td>14.32±0.63^*</td>
<td>0.562±0.01^*</td>
<td>0.249±0.01^*</td>
<td>0.211±0.008^*</td>
<td>-0.821±0.04^*</td>
<td>0.503±0.03^*</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td>8.1±0.31^*</td>
<td>0.728±0.03^*</td>
<td>0.123±0.004^*</td>
<td>0.149±0.006^*</td>
<td>-0.374±0.008^*</td>
<td>0.542±0.02^*</td>
</tr>
<tr>
<td>Group 2</td>
<td></td>
<td></td>
<td>13.21±0.65^*</td>
<td>0.58±0.02^*</td>
<td>0.224±0.01^*</td>
<td>0.194±0.008^*</td>
<td>-0.71±0.03^*</td>
<td>0.495±0.02^*</td>
</tr>
<tr>
<td></td>
<td>I</td>
<td></td>
<td>14.25±0.69^*</td>
<td>0.546±0.02^*</td>
<td>0.292±0.01^*</td>
<td>0.162±0.007^*</td>
<td>-0.832±0.03^*</td>
<td>0.616±0.02^*</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td>8.66±0.38^*</td>
<td>0.756±0.03^*</td>
<td>0.118±0.04^*</td>
<td>0.126±0.004^*</td>
<td>-0.323±0.01^*</td>
<td>0.719±0.03^*</td>
</tr>
<tr>
<td>Group 3</td>
<td></td>
<td></td>
<td>7.26±0.28^*</td>
<td>0.773±0.03^*</td>
<td>0.117±0.005</td>
<td>0.110±0.003^*</td>
<td>-0.293±0.01^*</td>
<td>0.920±0.03^*</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td>13.23±0.77^*</td>
<td>0.534±0.02^*</td>
<td>0.252±0.01^*</td>
<td>0.214±0.01^*</td>
<td>-0.873±0.04^*</td>
<td>0.760±0.02^*</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td></td>
<td>6.81±0.26^*</td>
<td>0.780±0.03^*</td>
<td>0.110±0.003^*</td>
<td>0.110±0.003^*</td>
<td>-0.282±0.01^*</td>
<td>0.854±0.03^*</td>
</tr>
<tr>
<td>Group 4</td>
<td></td>
<td></td>
<td>16.46±0.81^*</td>
<td>0.520±0.02^*</td>
<td>0.250±0.05^*</td>
<td>0.230±0.01^*</td>
<td>-0.923±0.03^*</td>
<td>0.732±0.02^*</td>
</tr>
</tbody>
</table>

* Type of SCFA changes; ^ P<0.05 vs. control; * P<0.05 between Groups 1 and 2; # P<0.05 between Groups 3 and 4.

Changes in SCFA were obviously due to the increase in activity of anaerobes and activity of aerobic microflora with a strong protolithic and hemolytic activity.

There was a progressive increase in the frequency of the Type 3 SCFA disorders with the increase of the LPO severity (Table 2). In particular, the Type 1 SCFA disorders occurred only in patients with the reticular and exudative-hyperemic forms of OLP. In patients with the reticular form of OLP, the frequency of Type 3 SCFA disorders was 44.44±8.28% in comparison with Type I (22.22±6.93%, P<0.05). In patients with the exudative-hyperemic form of OLP, the frequency of Type 3 SCFA disorders was 52.94±8.56% in comparison with Type I (11.76±5.52%, P<0.05). The frequency of Type 3 and Type 2 disorders was 70.37±8.8% vs. 29.63±8.79% (P<0.05) for the erosive-ulcerative form and 61.90±7.50% vs. 38.10±7.56% (P<0.05) for the bullous form of OLP (Table 2).

Table 2.
Changes in the SCFA spectrum in association with different clinical forms of OLP

<table>
<thead>
<tr>
<th>Type</th>
<th>Clinical form of OLP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group 1 (n=36)</td>
</tr>
<tr>
<td>I</td>
<td>8(22.2±6.93)*</td>
</tr>
<tr>
<td>II</td>
<td>12(33.3±7.85)</td>
</tr>
<tr>
<td>III</td>
<td>16(44.4±8.28)</td>
</tr>
<tr>
<td>Total</td>
<td>36(100)</td>
</tr>
</tbody>
</table>

* Type of SCFA changes; values are presented as n(%); # P<0.05 between Types 1 and 3; * P<0.05 between Types 1 and 2; ^ P<0.05 between Types 2 and 3; ** P<0.05 versus Group 1.

Discussion

Manifestations of OLP are rarely isolated. Patients with OLP often have the comorbid diseases, including disorders in the GIT, which are found between 15% and 80% of patients, according to the data of different authors [20-23].

The presence of co-morbidity of different parts of the digestive tract is inevitably accompanied by dysbiosis in the mouth and intestines. Several authors have identified the expressed disbiotic disorders in the oral cavity with OLP [24-27]. Breakdown of the normal microbial community increases the risk of pathogen infection, the overgrowth of harmful pathobionts, and immuno-inflammatory disease. Understanding the interaction of the microbiota with pathogens and the host might provide new insights into the pathogenesis of systemic disorders.

In general terms, patients with LPO exhibit abnormal microbiota with instability of dominant species, which is higher than in healthy controls. High fecal concentrations of total or individual SCFAs might also be the result of increased microbial production, shifts in microbial cross-feeding patterns, and low mucosal absorption. Nevertheless, it is known that changes in the concentration and proportion of individual SCFAs are concurrent with changes in bacterial groups.

SCFAs present multiple effects in different cells involved in the inflammatory and immune responses. In general, SCFAs, such as propionate and butyrate, inhibit stimuli-induced expression of adhesion molecules and chemokine production, and consequently suppress monocyte/macrophage and neutrophil recruitment, suggesting an anti-inflammatory action. However, there is also evidence in favor of a pro-inflammatory action of SCFAs in some conditions [17,28]. This discrepancy may be in part explained by the ability of SCFAs to induce neutrophil migration. In sites of anaerobic bacteria infection or after loss of intestinal epithelial integrity, high concentrations of SCFAs may lead to neutrophil accumulation and amplification of the inflammatory process [18]. Another possible explanation is that these fatty acids may present divergent effects depending on the cell type (e.g., anti- and pro-inflammatory effects of SCFAs on macrophage and microglial cells have been demonstrated [29-31]. Therefore, although SCFAs modulate the function of immune cells, more studies are necessary in order to understand the precise role of SCFAs on the interaction between bacteria and host.
immune cells in vivo, particularly in the GI tract and in sites of anaerobic infections, including the skin and oral cavity [18].

In conclusion, changes in the qualitative and quantitative contents of SCFAs reflect the disturbances in gut microbiocenosis in LPO patients, which may be one cause for aggravation of the pathological process.

Competing interests
The authors declare that they have no competing interests.

References